Finbarr E. Cotter

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

Andrew Webb, David Cunningham, Finbarr E. Cotter et al. · The Lancet · 1997 · 498 citations

Bcl-2 Antisense Therapy, Lymphoid Neoplasia, Medicine +4

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

Justin S. Waters, Andrew Webb, David Cunningham et al. · Journal of Clinical Oncology · 2000 · 455 citations

The 11q terminal deletion disorder: A prospective study of 110 cases

Paul Grossfeld, Teresa Mattina, Zona Lai et al. · American Journal of Medical Genetics Part A · 2004 · 343 citations

Genetic Epidemiology, Diagnosis, Platelet Dysfunction +18

First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial

Amy Webb, David Cunningham, Finbarr E. Cotter et al. · European Journal of Cancer · 1997 · 320 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

t(11;18)(q21;q21) is the most common translocation in MALT lymphomas

Iwona Auer, Randy D. Gascoyne, J.M. Conners et al. · Annals of Oncology · 1997 · 257 citations

Lymphoid Neoplasia, Medicine, Immunology +6